Scinai Doubles CDMO Revenue, Expands with Recipharm Acquisition
Event summary
- CDMO revenues doubled year-over-year to $1.3 million in 2025.
- Acquired Recipharm Israel in February 2026, expanding small-molecule capabilities.
- Resubmitted FENG grant application for PC111 with €12 million potential funding.
- Net loss of $8.3 million in 2025, down from $4.8 million net income in 2024.
- Extended option agreement with Pincell for PC111 program to August 2026.
The big picture
Scinai's dual R&D/CDMO model aims to balance therapeutic innovation with revenue-generating services. The Recipharm acquisition strengthens its position in the competitive CDMO space, while grant-funded pipeline development targets capital efficiency. The biotech manufacturing sector continues to consolidate, with integrated service providers gaining market share.
What we're watching
- CDMO Scaling
- Whether Scinai can sustain CDMO revenue growth post-Recipharm integration.
- Grant Approval
- The pace at which FENG grant applications advance PC111 and IL-17 programs.
- Pipeline Focus
- How PC111's flagship status impacts NanoAbs platform development.
Related topics